Bank of America Merrill Lynch Maintains Buy on Express Scripts

Bank of America Merrill Lynch is out with its report today on Express Scripts

, maintaining Buy. In its report, Bank of America Merrill Lynch writes, "ESRX's earnings, cash flow and ROIC trends should benefit from a bolus of branded patent expiries over the next 12 months, the ability to capture incremental supply chain efficiencies, a double digit specialty pharmacy cost trend, and ongoing capital deployment initiatives." Bank of America Merrill Lynch maintains a $65 PO on ESRX. Shares of ESRX closed Tuesday at $45.40, down 0.13% from Friday's close.